Diabetic Retinopathy: Pipeline Review, H1 2018 - Therapeutics Development & Assessment, Drug Profiles and Companies Involved - ResearchAndMarkets.com

June 5, 2018

DUBLIN--(BUSINESS WIRE)--Jun 5, 2018--The “Diabetic Retinopathy - Pipeline Review, H1 2018” report has been added to ResearchAndMarkets.com’s offering.

Diabetic Retinopathy - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Diabetic Retinopathy (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Retinopathy (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Retinopathy and features dormant and discontinued projects.

The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 9, 7, 47, 12 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 1 molecules, respectively.

Key Topics Covered

Introduction Diabetic Retinopathy - Overview Diabetic Retinopathy - Therapeutics Development Diabetic Retinopathy - Therapeutics Assessment Diabetic Retinopathy - Companies Involved in Therapeutics Development Diabetic Retinopathy - Drug Profiles Diabetic Retinopathy - Dormant Projects Diabetic Retinopathy - Discontinued Products Diabetic Retinopathy - Product Development Milestones Appendix

Companies Mentioned

Abzena Plc Acucela Inc Aerie Pharmaceuticals Inc Antisense Therapeutics Ltd Applied Therapeutics Inc BCN Peptides SA Boehringer Ingelheim GmbH Charlesson LLC Coherus BioSciences Inc Crinetics Pharmaceuticals Inc Dynamis Therapeutics Inc EyeGene Inc EyePoint Pharmaceuticals Inc F. Hoffmann-La Roche Ltd Formycon AG IMMD Inc Kodiak Sciences Inc Kowa Co Ltd Lupin Ltd Medy-Tox Inc Nemus Bioscience Inc NGM Biopharmaceuticals Inc Oculis ehf OcuNexus Therapeutics Inc PanOptica Inc Profarma Promedior Inc Protheragen Inc Regeneron Pharmaceuticals Inc Rezolute Inc Ribomic Inc Strongbridge Biopharma plc Sylentis SAU ThromboGenics NV VESSL Therapeutics Ltd

For more information about this report visit https://www.researchandmarkets.com/research/nfwl6d/diabetic?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180605006349/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs,Optical Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/05/2018 12:08 PM/DISC: 06/05/2018 12:08 PM


Update hourly